Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma

Summary

The study aims at:

1. Perform a multilayer analysis relying on tight integration of in-depth multi-omics approaches with clinical data to discover immune markers, with attention to age and sex differences, predicting prognosis and defining key life/environmental elements, to guide AI-driven personalised treatments and ensure improved care and QoL of glioblastoma patients.
2. To deepen glioblastoma knowledge through the study of glioblastoma stem cell cultures and to assess the sensitivity of glioblastoma stem cell cultures to a number of chemotherapeutics in different experimental conditions.
3. To create a comprehensive, stakeholder-generated guidelines for the ethical use of patient data for artificial intelligence-assisted prediction systems in glioblastoma, including an online, easily accessible patient information brochure to increase patient empowerment in the field.

Conditions

• Glioblastoma, IDH-wildtype

Interventions

OTHER

Biological biomarker analysis

Collection of tumor and blood samples at T0 (surgery) and T1 (6 months follow-up) Tumor microenvironment and blood multi-omics analysis In-depth functional characterization of tumor microenvironment Cancer stem cells generation and drug testing Data integration by business intelligence and development of AI-based prognostic markers

Sponsors & Collaborators

• Oslo University Hospital

  collaborator OTHER

• Istituto Superiore di Sanità

  collaborator OTHER

• Luxembourg Institute of Health

  collaborator OTHER_GOV

• Hospital Donostia

  collaborator OTHER

• University Medical Center Goettingen

  collaborator OTHER

• National Research Council

  collaborator UNKNOWN

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS

  lead OTHER

Principal Investigators

• Quintino Giorgio D'Alessandris, MD, PhD · Fondazione Policlinico Universitario A. Gemelli, IRCCS

Study Design

Allocation

NA

Purpose

BASIC_SCIENCE

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-02-29

Primary Completion

2026-05-30

Completion

2026-12-30

Countries

• Italy

Study Locations